Life Sciences

Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
April 21, 2021
ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.
April 20, 2021
ITIF hosted an expert panel discussion to explore the economic, health, and social effects that may persist post-COVID.
April 19, 2021
Blood-based multi-cancer early detection (MCED) technologies hold the promise to revolutionize America’s cancer-screening paradigm, dramatically expanding the range of detectable cancers and identifying them at earlier stages when cancers are more treatable. Policymakers should provide a supportive regulatory and coverage environment.
April 9, 2021
The United States and other developed, democratic societies have a moral obligation to ensure the world’s citizens receive COVID-19 vaccines and therapeutics. But there is absolutely no need to abrogate IP rights to fulfill that objective.
April 2, 2021
Intellectual property has proved to be indispensable in developing effective vaccines and therapeutics. Nevertheless, advocates have seized the moment to petition the WTO’s TRIPS Council not just to suspend patents, but also to reform national copyright laws governing digital access to knowledge, and data and text mining.
March 25, 2021
ITIF and the Bayh-Dole Coalition hosted a joint video webinar that will clarify the provision’s intent and explain once and for all how Bayh-Dole’s march-in right can and cannot be used.
March 23, 2021
ITIF commends NIST for taking steps to codify the clearly proscribed and intentionally limited intent and parameters of march-in rights as they pertain to the Bayh-Dole Act.
March 9, 2021
Amidst an unprecedented pace of innovation, some 90 developing nations, led by India and South Africa, have petitioned the WTO’s TRIPS Council calling for a waiver to suspend all IP rights associated with COVID-19 innovations—again asserting the false narrative that IP rights inhibit access to medicines.
March 8, 2021
These strong effects point to the tremendous spillover benefits that medical innovations have on the labor market and the economy as a whole.
February 18, 2021
Stephen Ezell and Jaci McDole presented about Intellectual Property’s Impact on Global Health and Life-sciences Innovation to students at the University of Akron Law School on February 18, 2021.

Pages